Skye Bioscience, Common Stock Book Value Per Share
| SKYE Stock | USD 2.46 0.20 7.52% |
Skye Bioscience, Common fundamentals help investors to digest information that contributes to Skye Bioscience,'s financial success or failures. It also enables traders to predict the movement of Skye Stock. The fundamental analysis module provides a way to measure Skye Bioscience,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Skye Bioscience, stock.
| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.30) | (0.32) | |
| Tangible Book Value Per Share | (0.30) | (0.32) |
Skye | Book Value Per Share |
Skye Bioscience, Common Company Book Value Per Share Analysis
Skye Bioscience,'s Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Skye Bioscience, Book Value Per Share | 2.50 X |
Most of Skye Bioscience,'s fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Skye Bioscience, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Skye Book Value Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Skye Bioscience, is extremely important. It helps to project a fair market value of Skye Stock properly, considering its historical fundamentals such as Book Value Per Share. Since Skye Bioscience,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Skye Bioscience,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Skye Bioscience,'s interrelated accounts and indicators.
Click cells to compare fundamentals
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
Skye Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, the book value per share of Skye Bioscience, Common is about 2.499 times. This is 247.0% lower than that of the Biotechnology sector and 101.01% lower than that of the Health Care industry. The book value per share for all United States stocks is 99.87% higher than that of the company.
Skye Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Skye Bioscience,'s direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Skye Bioscience, could also be used in its relative valuation, which is a method of valuing Skye Bioscience, by comparing valuation metrics of similar companies.Skye Bioscience, is currently under evaluation in book value per share category among its peers.
Skye Bioscience, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Skye Bioscience,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Skye Bioscience,'s managers, analysts, and investors.Environmental | Governance | Social |
Skye Fundamentals
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 7.41 M | ||||
| Shares Outstanding | 30.34 M | ||||
| Shares Owned By Insiders | 1.89 % | ||||
| Shares Owned By Institutions | 85.41 % | ||||
| Number Of Shares Shorted | 1.77 M | ||||
| Price To Book | 0.98 X | ||||
| EBITDA | (13.55 M) | ||||
| Net Income | (37.64 M) | ||||
| Cash And Equivalents | 2.93 M | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 4.62 M | ||||
| Debt To Equity | 0.84 % | ||||
| Current Ratio | 0.91 X | ||||
| Book Value Per Share | 2.50 X | ||||
| Cash Flow From Operations | (13.95 M) | ||||
| Short Ratio | 5.76 X | ||||
| Earnings Per Share | (3.60) X | ||||
| Target Price | 18.0 | ||||
| Number Of Employees | 11 | ||||
| Beta | 1.75 | ||||
| Market Capitalization | 163.52 M | ||||
| Total Asset | 11.94 M | ||||
| Retained Earnings | (104.38 M) | ||||
| Working Capital | (2.25 M) | ||||
| Net Asset | 11.94 M |
About Skye Bioscience, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Skye Bioscience, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Skye Bioscience, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Skye Bioscience, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Skye Bioscience, Common is a strong investment it is important to analyze Skye Bioscience,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Skye Bioscience,'s future performance. For an informed investment choice regarding Skye Stock, refer to the following important reports:Check out Skye Bioscience, Piotroski F Score and Skye Bioscience, Altman Z Score analysis. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Skye Bioscience,. If investors know Skye will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Skye Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.60) | Return On Assets (0.30) | Return On Equity (0.55) |
The market value of Skye Bioscience, Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Skye Bioscience,'s market value can be influenced by many factors that don't directly affect Skye Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Skye Bioscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Skye Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Skye Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.